110 related articles for article (PubMed ID: 6162543)
61. The effect of 5-fluorouracil on inhibition of epidermal DNA synthesis in vivo: a comparison of the effect of formulations and a prodrug of 5-FU.
Sloan KB; Sherertz EF; McTiernan RG
Arch Dermatol Res; 1990; 282(7):484-6. PubMed ID: 2078053
[No Abstract] [Full Text] [Related]
62. Enhancement and depression by inosine of the growth inhibitory action of 5-fluorouracil on cultured Jensen tumor cells.
Beltz RE; Waters RN; Hegarty TJ
Biochem Biophys Res Commun; 1983 Apr; 112(1):235-41. PubMed ID: 6838609
[TBL] [Abstract][Full Text] [Related]
63. Experimental parasynchronization in cultures of HeLa cells and mouse lymphosarcoma cells.
Nakano M
Mie Med J; 1965 Sep; 15(2):77-88. PubMed ID: 5869849
[No Abstract] [Full Text] [Related]
64. [Dynamics of cell division anomalies in cells of the JBK ascites tumor of the mouse].
Kövi J; Kovács M
Arch Geschwulstforsch; 1964; 23(3):181-7. PubMed ID: 5827423
[No Abstract] [Full Text] [Related]
65. Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity.
Houghton JA; Houghton PJ
Prog Cell Cycle Res; 1996; 2():175-85. PubMed ID: 9552394
[TBL] [Abstract][Full Text] [Related]
66. Non-gradient regional differences in tumor growth.
Yang TJ
In Vivo; 1987; 1(1):53-5. PubMed ID: 2979765
[TBL] [Abstract][Full Text] [Related]
67. Vanoxonin, a new inhibitor of thymidylate synthetase. II. Structure determination and total synthesis.
Kanai F; Isshiki K; Umezawa Y; Morishima H; Naganawa H; Takita T; Takeuchi T; Umezawa H
J Antibiot (Tokyo); 1985 Jan; 38(1):31-8. PubMed ID: 3972726
[TBL] [Abstract][Full Text] [Related]
68. In vivo rates of pyrimidine nucleotide metabolism in intact mouse T-lymphoma (s-49) cells treated with 5-fluorouracil.
Maybaum J; Cohen MB; Sadee W
J Biol Chem; 1981 Mar; 256(5):2126-30. PubMed ID: 6970198
[No Abstract] [Full Text] [Related]
69. [Radiotherapy following synchronization and its theoretical prerequisites].
Nitze HR; Ganzer U; Vosteen KH
Fortschr Geb Rontgenstr Nuklearmed; 1972; ():Suppl:201-2. PubMed ID: 4341102
[No Abstract] [Full Text] [Related]
70. Effects of 1-(halogenalkoxy)alkyl-5-fluorouracil derivatives on cell growth, cell volume and nucleus size of mouse lymphoma cells.
Reitz M; Jaeger KH
Chemotherapy; 1992; 38(1):57-65. PubMed ID: 1618004
[TBL] [Abstract][Full Text] [Related]
71. Influence of duration of exposure to 5-fluorouracil on antiproliferating activity against cultured murine lymphoma cells.
Kanzawa F; Hoshi A; Kuretani K
Br J Cancer; 1981 Nov; 44(5):757-9. PubMed ID: 7317275
[No Abstract] [Full Text] [Related]
72. 30 years of 5-fluorouracil.
Wasternack C; Hause B
Pharmazie; 1987 Feb; 42(2):73-9. PubMed ID: 3602063
[No Abstract] [Full Text] [Related]
73. Studies on the mechanism of fluoropyrimidine cytotoxicity in l1210 cells: correlation with inhibition of thymidylate synthetase but not with incorporation into RNA.
Danenberg KD; Becker D; Mulkins MA; Danenberg PV
Pharm Res; 1984 May; 1(3):110-5. PubMed ID: 24277246
[TBL] [Abstract][Full Text] [Related]
74. A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
Patel K; Yerram SR; Azad NA; Kern SE
Oncotarget; 2012 Jul; 3(7):678-85. PubMed ID: 22824673
[TBL] [Abstract][Full Text] [Related]
75. 5-Fluorouracil incorporated into the tissue RNA of human and rat bladder carcinoma after administration of 1-(2-tetrahydrofuryl)-5-fluorouracil combined with uracil.
Tsujimoto S; Fujimoto K; Okajima E; Ozono S; Okajima E; Hirao Y
Int J Clin Oncol; 2008 Apr; 13(2):138-43. PubMed ID: 18463958
[TBL] [Abstract][Full Text] [Related]
76. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
Grem JL
Invest New Drugs; 2000 Nov; 18(4):299-313. PubMed ID: 11081567
[TBL] [Abstract][Full Text] [Related]
77. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum.
Jiang L; Lee PC; White J; Rathod PK
Antimicrob Agents Chemother; 2000 Apr; 44(4):1047-50. PubMed ID: 10722510
[TBL] [Abstract][Full Text] [Related]
78. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.
Mirjolet JF; Barberi-Heyob M; Merlin JL; Marchal S; Etienne MC; Milano G; Bey P
Br J Cancer; 1998 Jul; 78(1):62-8. PubMed ID: 9662252
[TBL] [Abstract][Full Text] [Related]
79. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
Kinsella AR; Smith D; Pickard M
Br J Cancer; 1997; 75(7):935-45. PubMed ID: 9083327
[TBL] [Abstract][Full Text] [Related]
80. Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
Okayasu T; Sugiyama K; Miyauchi S
Jpn J Cancer Res; 1994 Jan; 85(1):101-5. PubMed ID: 8106287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
